To cite this paper use one of the standards below:
Epilepsy is a worldwide disease. About 30% of these patients do not respond to treatment due to the influence of efflux transporters, especially P-glycoprotein (Pg-P), of which antiepileptics are substrates. Given the above, the present work aimed to evaluate the pharmacokinetics of carbamazepine, comparing healthy and epileptic rats, and the use of Pg-P inhibitors. (Protocol Ethics Committee CEUA/UNIFAL-MG No. 32/2017). Carbamazepine was administered 25 mg/kg to healthy and epileptic animals, induced by chemical model of pilocarpine-induced epilepsy. The pharmacokinetics of carbamazepine administered together with Pg-P inhibitor verapamil were also evaluated. Blood samples were taken from 0-8 hours. The analysis was done in UHPLC-MS/MS. No statistical differences were observed between the control and epileptic groups, even with the use of Pg-P inhibitor. These results may be explained by the fact that carbamazepine is not an ideal Pg-P substrate in rats.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper